Brain microbleeds as a potential risk factor for antiplatelet-related intracerebral haemorrhage: hospital-based,

S M Gregoire1, H R Jäger, T A Yousry

  • 1Stroke Research Group, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

Abstract

Insights

Brain microbleeds detected by MRI are linked to a higher risk of intracerebral haemorrhage (ICH) in patients taking antiplatelet medication. Identifying these microbleeds may help predict ICH risk before starting antiplatelet therapy.

Area of Science:

  • Neurology
  • Radiology
  • Cardiovascular Medicine

Background:

  • Intracerebral haemorrhage (ICH) is a severe complication of antiplatelet therapy.
  • Brain microbleeds on MRI are potential biomarkers for small-vessel disease and bleeding risk.
  • Identifying patients at high risk for ICH is crucial to mitigate treatment hazards.

Purpose of the Study:

  • To investigate whether brain microbleeds are a risk factor for antiplatelet-related ICH.
  • To assess the association between microbleeds and the occurrence of ICH in patients using antiplatelet drugs.

Main Methods:

  • A hospital-based, matched case-control study was conducted.
  • Cases of spontaneous ICH were identified from a prospective database.
  • Two controls per case were matched for age, sex, and hypertension, without prior ICH or antiplatelet use; microbleeds were assessed by a blinded observer.

Main Results:

  • Microbleeds were significantly more frequent in patients with antiplatelet-related ICH (81%) compared to controls (19%) and non-antiplatelet-related ICH (45%).
  • The number of microbleeds was associated with an increased risk of antiplatelet-related ICH (adjusted OR 1.33 per additional microbleed).
  • Lobar microbleeds were also more common in the antiplatelet-related ICH group.

Conclusions:

  • Brain microbleeds are significantly associated with an increased risk of intracerebral haemorrhage in patients using antiplatelet therapy.
  • A high number of lobar microbleeds may indicate that the risks of antiplatelet therapy outweigh the benefits.
  • Further prospective studies are recommended to confirm the prognostic value of microbleeds in regular antiplatelet users.